Summary
Boston Scientific Corporation (BSX) reported strong financial results for the quarter and six months ended June 30, 2023. Net sales increased by 11.0% in the second quarter and 11.5% for the first six months, driven by robust operational net sales growth across its diverse product portfolio and strategic acquisitions. The company demonstrated improved profitability, with gross profit margin increasing to 70.6% in Q2 2023 from 68.8% in Q2 2022, attributed to favorable sales mix and higher-margin product sales. The company successfully integrated recent acquisitions, including Apollo Endosurgery, Inc. and a majority stake in Acotec, which are expected to contribute to future growth. Despite ongoing global economic uncertainties, including supply chain disruptions and inflationary pressures, BSX maintained strong operational execution and financial discipline. The company also highlighted its commitment to innovation, with continued investment in research and development, aiming to maintain a pipeline of new products. BSX also reported compliance with its financial covenant and sufficient liquidity for its operational needs.
Financial Highlights
50 data points| Revenue | $3.60B |
| Cost of Revenue | $1.06B |
| Gross Profit | $2.54B |
| SG&A Expenses | $1.35B |
| Operating Expenses | $2.03B |
| Operating Income | $514.00M |
| Interest Expense | $70.00M |
| Net Income | $270.00M |
| EPS (Basic) | $0.18 |
| EPS (Diluted) | $0.18 |
| Shares Outstanding (Basic) | 1.45B |
| Shares Outstanding (Diluted) | 1.46B |
Key Highlights
- 1Net sales increased by 11.0% to $3.599 billion for the second quarter and 11.5% to $6.988 billion for the first six months of 2023, driven by strong operational and organic growth.
- 2Gross profit margin improved to 70.6% for the second quarter of 2023 (from 68.8% in Q2 2022) and 70.0% for the first six months of 2023 (from 68.6% in H1 2022), reflecting favorable product mix and higher-margin sales.
- 3The company completed the acquisition of Apollo Endosurgery, Inc. and a majority stake in Acotec, integrating them into its Endoscopy and Peripheral Interventions divisions, respectively.
- 4Operating income increased to $514 million for the second quarter and $1,066 million for the first six months, demonstrating effective cost management and revenue growth.
- 5The company reported compliance with its financial leverage ratio covenant (2.48x actual vs. 3.75x maximum permitted) and maintained sufficient liquidity.
- 6Research and Development expenses increased by 7% in Q2 and 6% in H1 2023, underscoring the company's commitment to innovation and future product pipeline development.
- 7All outstanding Mandatory Convertible Preferred Stock (MCPS) automatically converted into common stock on June 1, 2023, simplifying the capital structure.